Lin28/let-7/Bcl-xL pathway: The underlying mechanism of drug resistance in Hep3B cells

Oncology Reports

Volumn 32, Issue 3, 2014, Pages 1050-1056

  Tian, Nan ^a   Han, Ziwu ^a   Li, Zhaohui ^b   Zhou, Mingjie ^a   Fan, Chunlei ^a  

^a ZHEJIANG CHINESE MEDICAL UNIVERSITY   (China)

^b JILIN UNIVERSITY   (China)

Author keywords

Bcl xL; Drug resistance; Hepatocellular carcinoma; Let 7 family; Lin28

Indexed keywords

ANTINEOPLASTIC AGENT; BINDING PROTEIN; CASPASE 3; CASPASE 9; CISPLATIN; CYCLOPHOSPHAMIDE; CYTOCHROME C; FLUOROURACIL; LET 7 PROTEIN; LIN28 PROTEIN; MICRORNA; PACLITAXEL; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL XL; UNCLASSIFIED DRUG; BCL2L1 PROTEIN, HUMAN; LIN-28 PROTEIN, HUMAN; MIRNLET7 MICRORNA, HUMAN; PROTEIN BCL X; RNA BINDING PROTEIN;

APOPTOSIS; ARTICLE; BIOGENESIS; CANCER CHEMOTHERAPY; CELL VIABILITY; CHEMOEMBOLIZATION; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IC 50; LIVER CELL CARCINOMA; MOLECULAR MECHANICS; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; UPREGULATION; WESTERN BLOTTING; CARCINOMA, HEPATOCELLULAR; DRUG EFFECTS; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENETICS; LIVER NEOPLASMS; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; BCL-X PROTEIN; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CISPLATIN; CYCLOPHOSPHAMIDE; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LIVER NEOPLASMS; MICRORNAS; PACLITAXEL; RNA-BINDING PROTEINS; UP-REGULATION;

EID: 84923068160     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2014.3292     Document Type: Article

References (20)

1. Poon D, Anderson BO, Chen LT, et al: Management of hepatocellular carcinoma in Asia: consensus statement from the Asian Oncology Summit 2009. Lancet Oncol 10: 1111-1118, 2009.
2. Cammà C, Schepis F, Orlando A, Albanese M, Shahied L, Trevisani F, Andreone P, Craxì A and Cottone M: Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials. Radiology 224: 47-54, 2002. (Pubitemid 34680374)
3. Lin HL, Lui WY, Liu TY and Chi CW: Reversal of Taxol resistance in hepatoma by cyclosporine A: involvement of the PI-3 kinase-AKT 1 pathway. Br J Cancer 88: 973-980, 2003.
4. Yang X, Lin X, Zhong X, et al: Double-negative feedback loop between reprogramming factor LIN28 and microRNA let-7 regulates aldehyde dehydrogenase 1-positive cancer stem cells. Cancer Res 70: 9463-9472, 2010.
5. Lv K1, Liu L, Wang L, et al: Lin28 mediates paclitaxel resistance by modulating p21, Rb and Let-7a miRNA in breast cancer cells. PLoS One 7: e 40008, 2012.
6. Teng RY, Zhou JC, Jiang ZN, Xu CY, Li ZD, Wang QC, Xu CP, Guo JF, Shen JG and Wang LB: The relationship between Lin28 and the chemotherapy response of gastric cancer. Onco Targets Ther 6: 1341-1345, 2013.
7. Viswanathan SR, Powers JT, Einhorn W, Hoshida Y, Ng TL, Toffanin S, et al: Lin28 promotes transformation and is associated with advanced human malignancies. Nat Genet 41: 843-848, 2009.
8. Viswanathan SR, Daley GQ and Gregory RI: Selective blockade of microRNA processing by Lin28. Science 320: 97-100, 2008. (Pubitemid 351490762)
9. Heo I, Joo C, Cho J, Ha M, Han J and Kim VN: Lin28 mediates the terminal uridylation of let-7 precursor microRNA. Mol Cell 32: 276-284, 2008.
10. Shimizu S, Takehara T, Hikita H, et al: The let-7 family of microRNAs inhibits Bcl-xL expression and potentiates sorafenib-induced apoptosis in human hepatocellular carcinoma. J Hepatol 52: 698-704, 2010.
11. Tian N, Li X, Luo Y, Han Z, Li Z and Fan C: Curcumin regulates the metabolism of low density lipoproteins by improving the C-to-U RNA editing efficiency of apolipoprotein B in primary rat hepatocytes. Mol Med Rep 9: 132-136, 2014.
12. Cavalieri EL, Stack DE, Devanesan PD, et al: Molecular origin of cancer: catechol estrogen-3,4-quinones as endogenous tumor initiators. Proc Natl Acad Sci USA 94: 10937-10942, 1997. (Pubitemid 27430839)
13. Kool M1, de Haas M, Scheffer GL, Scheper RJ, van Eijk MJ, Juijn JA, Baas F and Borst P: Analysis of expression of cMOAT (MRP2), MRP3, MRP4, and MRP5, homologues of the multidrug resistance-associated protein gene (MRP1), in human cancer cell lines. Cancer Res 57: 3537-3547, 1997.
14. Lin HL, Liu TY, Lui WY and Chi CW: Up-regulation of multidrug resistance transporter expression by berberine in human and murine hepatoma cells. Cancer 85: 1937-1942, 1999.
15. Zhang J, Zhao J, Zhang W, Liu G, Yin D, Li J, Zhang S and Li H: Establishment of paclitaxel-resistant cell line and the underlying mechanism on drug resistance. Int J Cynecol Cancer 22: 1450-1456, 2012.
16. Işri OD, Kars MD, Eroglu S and Gündüz U: Drug resistant MCF-7 cell lines also developed cross-resistance to structurally unrelated anticancer agents. UHOD 19: 1-8, 2009.
17. Andersen MH, Becker JC and Straten Pt: Regulators of apoptosis: suitable targets for immune therapy of cancer. Nat Rev Drug Discov 4: 399-409, 2005.
18. Liu K, Qian T, Tang L, Wang J, Yang H and Ren J: Decreased expression of microRNA let-7i and its association with chemotherapeutic response in human gastric cancer. World J Surg Oncol 10: 225, 2012.
19. Takehara T, Liu X, Fujimoto J, Friedman SL and Takahashi H: Expression and role of Bcl-xL in human hepatocellular carcinomas. Hepatology 34: 55-61, 2001. (Pubitemid 32591483)
20. Lessene G, Czabotar PE and Colman PM: BCL-2 family antagonists for cancer therapy. Nat Rev Drug Discov 7: 989-1000, 2008.